Invention Grant
US08927495B1 Use of GnRH and analogs thereof for the prevention and treatment of pet ferret adrenocortical hyperplasia
有权
使用GnRH及其类似物预防和治疗宠物鼬肾上腺皮质增生
- Patent Title: Use of GnRH and analogs thereof for the prevention and treatment of pet ferret adrenocortical hyperplasia
- Patent Title (中): 使用GnRH及其类似物预防和治疗宠物鼬肾上腺皮质增生
-
Application No.: US13479577Application Date: 2012-05-24
-
Publication No.: US08927495B1Publication Date: 2015-01-06
- Inventor: Lowell A. Miller , Robert A. Wagner
- Applicant: Lowell A. Miller , Robert A. Wagner
- Applicant Address: US DC Washington US PA Pittsburgh
- Assignee: The United States of America as represented by the Secretary of Agriculture,Robert A. Wagner
- Current Assignee: The United States of America as represented by the Secretary of Agriculture,Robert A. Wagner
- Current Assignee Address: US DC Washington US PA Pittsburgh
- Agent John Fado; Randall E. Deck; Albert Y. Tsui
- Main IPC: A61K38/09
- IPC: A61K38/09 ; A61K38/10 ; A61K47/00 ; C07K7/00

Abstract:
Adrenocortical disease (ACD) in ferrets develops as a result of the effect of increased concentration of Luteinizing Hormone (LH) on adrenal LH receptors. This increase in LH often results from the neutering of male or female ferrets. Neutered ferrets have no negative feedback of the ovarian or testicular hormone and as a result LH is elevated 3 to 10 times normal. Elevated LH may be prevented and/or treated by injection of GnRH vaccine. Administration of GnRH produces antibodies to endogenous GnRH. The GnRH-anti-GnRH immune-complex is ineffective in stimulating the release of LH and FSH in the anterior pituitary resulting drop in concentration of LH in the systemic circulation. This reduction in LH significantly reduces the occurrence or clinical symptoms of ACD therein. Moreover, treatment of ferrets with the GnRH provides long term relief from ACD for a period of a year or more.
Information query
IPC分类: